Alise Reicin, MD, has been appointed senior vice president, head of Global Clinical Development at EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany. Dr. Reicin will report to Luciano Rossetti, head of Global R&D, and serve as a member of the R&D executive leadership team. She will be based in Billerica, MA.
 
Dr. Reicin will oversee the Clinical Development organization, including Therapeutic Areas; Evidence Value and Development; Biostatistics; Clinical Operations; and both the Japan and China R&D Hubs. In this capacity, she will lead the biopharmaceutical business of Merck KGaA, Darmstadt, Germany’s portfolio of pipeline programs.
 
Dr. Reicin brings research and early/late clinical development expertise, including experience in oncology and immunology. For the past 10 years she served as a vice president in various capacities across R&D at MSD (Merck Sharp & Dohme). Her experience complements Merck KGaA’s R&D strategy, which focuses on oncology, immuno-oncology and immunology, with several high-priority programs in late development, such as evofosfamide (TH-302) and avelumab (anti-PD-L1).
 
“We are honored to have Alise join us,” said Luciano Rossetti, head of Global Research and Development. “Her impressive experience across diverse areas of clinical research and operations will bring significant value to our organization. She is an accomplished executive whose leadership will serve to significantly advance our clinical development efforts and our strong commitment to enhance our R&D operating model.”